Literature DB >> 18670277

Bladder preserving strategies for muscle-invasive bladder cancer.

Axel S Merseburger1, Ira Matuschek, Markus A Kuczyk.   

Abstract

PURPOSE OF REVIEW: On average 20-30% of patients with non muscle-invasive bladder cancer will subsequently develop muscle-invasive disease with approximately 50% of the patients already bearing occult regional or distant metastases at that time. Few interdisciplinary centres are demonstrating multimodality bladder sparing approaches as equally effective when compared with radical cystectomy for muscle-invasive bladder cancer. RECENT
FINDINGS: So far no investigation could demonstrate prospective controlled data on long-term oncologic and functional outcomes comparing bladder-conserving strategies with radical cystectomy. It is evident that multimodality treatment regimens including a thoroughly performed transurethral resection of the bladder tumour, external beam radiation therapy, and chemotherapy can produce an increased amount of total costs in addition to the prolonged hospitalization of the patient during a trimodality bladder sparing approach. Therefore, in addition to the long-term oncological and functional outcome, the high costs of this approach together with the need for a very close cooperation between clinical disciplines and a highly compliant patient have to be taken in consideration.
SUMMARY: Without prospective controlled trials evaluating the long-term oncological results and the health-related quality of life for the multimodality treatment regimen for muscle-invasive bladder cancer, the radical surgical approach should still be considered as the standard treatment. Multimodality bladder preserving strategies might be a therapeutic option for carefully selected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670277     DOI: 10.1097/MOU.0b013e32830b86bd

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  5 in total

1.  Comparison of the short-term efficacy of sequential treatment with intravesical single-port laparoscopic partial cystectomy with bladder preservation or open partial cystectomy in combination with cisplatin plus gemcitabine chemotherapy.

Authors:  Hai-Xing Mai; Jun-LE Liu; Shu-Jun Pei; L I Zhao; Nan Qu; Jin-Kai Dong; Biao Chen; Ya-Lin Wang; Cheng Huang; Li-Jun Chen
Journal:  Exp Ther Med       Date:  2015-04-24       Impact factor: 2.447

2.  Green-laser assisted laparoscopic partial cystectomy for selective muscle-invasive bladder cancer: technique and initial outcome.

Authors:  Jinhai Fan; Kaijie Wu; Pu Zhang; Dalin He
Journal:  World J Urol       Date:  2019-11-15       Impact factor: 4.226

3.  [C-reactive protein prior to radical cystectomy: preoperative determination of CRP].

Authors:  M W Kramer; A Heinisch; G Wegener; M Abbas; C von Klot; I Peters; H Tezval; T R Herrmann; M A Kuczyk; A S Merseburger
Journal:  Urologe A       Date:  2014-02       Impact factor: 0.639

4.  Transurethral resection and degeneration of bladder tumour.

Authors:  Aihua Li; Wei Fang; Feng Zhang; Weiwu Li; Honghai Lu; Sikuan Liu; Hui Wang; Binghui Zhang
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

5.  Holmium laser-assisted laparoscopic partial cystectomy for bladder cancer: a single-institutional pilot study with technical feasibility and short-term oncological outcome.

Authors:  Kang Sup Kim; Sang Hoon Kim; Hyuk Jin Cho; Hong Jin Sur; Yong Sun Choi
Journal:  BMC Cancer       Date:  2022-02-21       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.